Research ArticleMolecular Imaging
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
Gaochao Lv, Xiaorong Sun, Ling Qiu, Yan Sun, Ke Li, Qingzhu Liu, Qi Zhao, Songbing Qin and Jianguo Lin
Journal of Nuclear Medicine January 2020, 61 (1) 117-122; DOI: https://doi.org/10.2967/jnumed.119.226712
Gaochao Lv
1Key Laboratory of Nuclear Medicine of Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China
Xiaorong Sun
2Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Ling Qiu
1Key Laboratory of Nuclear Medicine of Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China
Yan Sun
3Smart Nuclide Biotech, Suzhou, China; and
Ke Li
1Key Laboratory of Nuclear Medicine of Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China
Qingzhu Liu
1Key Laboratory of Nuclear Medicine of Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China
Qi Zhao
4Department of Radiation Oncology, First Affiliated Hospital of Soochow University, Suzhou, China
Songbing Qin
4Department of Radiation Oncology, First Affiliated Hospital of Soochow University, Suzhou, China
Jianguo Lin
1Key Laboratory of Nuclear Medicine of Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 1
January 1, 2020
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody
Gaochao Lv, Xiaorong Sun, Ling Qiu, Yan Sun, Ke Li, Qingzhu Liu, Qi Zhao, Songbing Qin, Jianguo Lin
Journal of Nuclear Medicine Jan 2020, 61 (1) 117-122; DOI: 10.2967/jnumed.119.226712
Jump to section
Related Articles
Cited By...
- The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook
- Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers
- First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
- Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma
- Single-Domain Antibody Theranostics on the Horizon
- Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
- Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?